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1269stopped with signiﬁcant artifact on a nonfocused and
off-axis frame shown in the display. With routine
clinical application of intracardiac echocardiography
in more than 3,000 cases of left heart ablation,
we noted that a right-to-left-ﬂow shunting of rASD can
be occasionally detected immediately following TC
(Figure 1) when a patient has signiﬁcantly increased
pulmonary artery systolic pressure (PASP) (Figures 1A
to 1C) or right heart dysfunction (Figures 1D to 1F).
Schueler et al. (1) did not provide clear hemodynamic
and cardiac functional evidence for worse clinical
outcome and increased mortality related to persistent
rASDwith further increased PASP, severity of tricuspid
regurgitation, or a right-to-left-ﬂow shunt at their 6-
month follow-up. Of note, Schueler et al. (1) provided
discrepant baseline echocardiographic measurements
between left ventricular diastolic volume (LVVd) and
end-diastolic dimension (LVEDD) for the patients with
rASD (191.6  75.3 ml and 7.3  0.7 cm, respectively)
and no rASD (198.4  80.2 ml and 6.1  0.7 cm,
respectively) in Table 3. The similar discrepancy is also
noted between LV systolic volume and LV end-systolic
dimension (LVESD) for these 2 patient groups. The
LVEDD and LVESD are clinically reliable parameters,
especially for patients with volume overload from
MR, which have been used as rough surrogates for pre-
load and afterload, respectively (4). These measure-
ment discrepancies make it difﬁcult to understand
which parameter is more accurate. However, in Ta-
ble 4, echocardiographic measurements of patients in
follow-up only used the LVVd parameter, without
including LVEDD measurements (1). Finally, in order
to properly interpret the cause of increased mortality
in these patients, the analysis should include all
available data through the last available follow-up
echocardiographic studies. Obviously, severe func-
tional MR and signiﬁcantly dilated LVEDD and LVESD
at baseline are associatedwith increasedmortality, not
necessarily related to rASD with left-to-right shunt.
Iatrogenic rASD and its clinical effects, especially
when using a large TC sheath, need further study. The
investigators should be congratulated for reporting a
high persistence of rASD at 6-month follow-up when
using 21-F TC sheath for the MitraClip procedure.
However, their data missed the opportunity for
quantitative assessment over time on the size and
ﬂow features of rASD. Care is needed to identify he-
modynamically signiﬁcant changes and their impact
on cardiac function and hemodynamics.*Jian-Fang Ren, MD
David J. Callans, MD
Francis E. Marchlinski, MD*Cardiac Electrophysiology Section
Division of Cardiovascular Medicine
University of Pennsylvania Health System
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1667–74.REPLY: Quantitative Evaluation of Residual
Atrial Septal Defect Following Transseptal
Catheterization for Intracardiac Interventional
ProceduresWe thank Dr. Ren and colleagues for the comment on
our paper (1).
Iatrogenic atrial septal defect (iASD) sizes were
considerably smaller in our study than Ren et al. (2)
found in previous analyses of procedures using
smaller transseptal sheaths. They found that iASDs
<4 mm had no clinical signiﬁcance. In our opinion,
the cited studies are not comparable to our results
due to the fact that we treated mainly typical heart
failure patients with a signiﬁcant proportion of pa-
tients with severely reduced left ventricular ejection
fraction (LVEF). Assuming that in our cohort, left
atrial pressures are signiﬁcantly higher than in a
healthier cohort, the hemodynamic consequences
and persistence rates may differ signiﬁcantly due to
markedly increased shunt volumes. In fact, the he-
modynamic relevance of ASD must not be calculated
based only on the sheer and may have overestimated
shunt sizes. Hemodynamic consequences are directly
related to the associated shunt volumes, and high-
ﬂow shunts with small diameters can lead to signiﬁ-
cant volume overload.
We cannot follow the comment of Dr. Ren and
colleagues We showed clearly a right-to-left shunting.
In our opinion, it is not suitable to compare
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1270periprocedural intracardiac echocardiography with
transesophageal echocardiography performed 6
months after transseptal puncture. We agree with
Ren et al. that it is not clear whether iASD persistence
accounts for adverse outcomes after MitraClip pro-
cedures or whether the persistence of an ASD just
reﬂects adverse conditions, which lead to higher
mortality and impaired functional outcomes.
The cited “discrepancies” between left ventric-
ular end-diastolic and end-systolic volumes in pa-
tients with or without iASD were not statistically
signiﬁcant, and therefore, it is highly hypothetical
to draw any conclusion from this ﬁnding, which
might be due to play of chance in a small patient
cohort. LVEF, derived from left ventricular end-
diastolic and end-systolic volumes, was entered
into regression analysis and failed to show signif-
icance for the prediction of 6-month mortality
rates.
Most of all, the aim of our study was to assess the
persistence rate of iASDs after MitraClip procedure
and to report a possible inﬂuence on functional
outcome. We did not aim to measure development of
ASD sizes and echocardiographic ﬂow features. We
doubt the reliability of 2-dimensional echocardio-
graphy for sizing small iASDs occurring in mobile
anatomical structures and echocardiography can only
give us a rough estimate of the true ASD sizes.
The hemodynamic consequences of ASDs should be
determined with invasive measures as depicted by
current guidelines (3,4).
We feel that our work contributes to a more careful
evaluation of patients with persistent iASD after
transseptal procedures, which might help lead to a
better understanding and, in addition, to increased
watchfulness regarding the clinical consequences of
interatrial shunting in such patients.Robert Schueler, MD
*Christoph Hammerstingl, MD
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Defect After MitraClip
TherapyAfter reading the recent paper in JACC: Cardiovascu-
lar Interventions by Schueler et al. (1) describing the
persistence of iatrogenic atrial septal defects (iASDs)
after MitraClip therapy, we wish to point out an
important omission. The authors stated that “persis-
tence rates of iASDs after MitraClip procedures [are]
unknown,” and “this is the ﬁrst study investigating
the persistence rates of iASD after interventional
edge-to-edge repair.” In fact, our group published the
ﬁrst investigation on this topic in 2012, and we were
surprised to see that our paper was not referenced in
the paper or accompanying editorial (2). We reported
on the incidence of iASD in 30 subjects undergoing
MitraClip repair during the roll-in phase of the
EVEREST II (Pivotal Study of a Percutaneous Mitral
Valve Repair System) randomized trial, who had
interpretable baseline, 30-day, and 6- and 12-month
transthoracic echocardiograms (TTE). We found that
iASDs were detectable in 27% of patients at 12 months
by TTE. Although this is lower than the 50% preva-
lence of iASD detected at 6 months by Schueler et al.
(1), their group used transesophageal echocardiogra-
phy, which is more sensitive for iASD detection.
Similar to Schueler et al. (1), we found that there was
less regression in left ventricular size in patients with
iASD. Importantly, we found that subjects with iASD
at 12 months had more residual mitral regurgitation
(MR), increased tricuspid regurgitation, and a trend
toward larger LA volumes than non-iASD patients.
Eighty-three percent of non-ASD patients were free
from MR >2þ at 12 months versus 38% of those with
iASD (p ¼ 0.016). We did not note any adverse clinical
events related to the presence of iASD. It is probably
fair to say that the true signiﬁcance of iASD remains
unknown and may be related to other procedural or
patient-level factors not well understood. Consider-
ation for transcatheter closure of iASD should be
